#6

OIPE
FEB 15 2002
PATENT & TRADEMARK OFFICE
JC48

Sheet 1 of 2

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: AL01019	SERIAL NO.: 09/955,383
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: ASLANIAN	
		FILING DATE: Sept. 18, 2001	GROUP: 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
H.L.	AA	4,767,778	8/88	U.S. PATENT	514	397	
H.L.	AB	5,352,707	10/94	U.S. PATENT	514	451	
H.L.	AC	5,869,479	2/99	U.S. PATENT			
	AD						
	AE						
	AF						

RECEIVED
FEB 20 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
H.L.	AG	WO 93/01812	2/93	INTERNATIONAL PATENT				
H.L.	AH	WO 93/12093	6/93	INTERNATIONAL PATENT				
H.L.	AI	WO 95/14007	5/95	INTERNATIONAL PATENT				
H.L.	AJ	WO 98/58646	12/98	INTERNATIONAL PATENT				
H.L.	AK	WO 96/29315	9/96	INTERNATIONAL PATENT				
H.L.	AL	EU 0448 765 B1	3/90	EUROPEAN PATENT				
H.L.	AM	EU 0 420 396 B1	7/90	EUROPEAN PATENT				
	AN							
	AO							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

H.L.	AP	Howson, Bioorganic & Medicinal Chemistry Letters, Two Novel, Potent and Selective Histamine H3 Receptor Agonists, Vol. 2, pp. 77-78, 1992.
H.L.	AQ	Stark, J. Med. Chem. , Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral In Vivo Activity, 39, pp. 1157-1163.
H.L.	AR	Sasse, Bioorganic & Medicinal Chemistry , (Partial) Agonist/Antagonist Properties of Novel Diarylalkyl, Vol 8 (2000) pp. 1139-1149.
H.L.	AS	Bagley, J. Med. Chem. 1991, New 1-(Heterocyclylalkyl)-4-(Propionanilido)-4-Piperidinyl, 34, pp 827-941.
H.L.	AT	Huls, Bioorganic & Medicinal Chemistry Letters, Diphenylmethyl Ethers: Synthesis and Histamine, Vol. 6, No. 16, pp. 2013-2018, 1996.
H.L.	AU	Buschauer, J. Med. Chem. 1989, Synthesis and in Vitro Pharmacology of Arpromidine, 32, pp 1963-1970, 1989.
H.L.		Schulze, Arch. Pharm. (Weinheim), Synthese und kombinierte H1/H2-antagonistische, Vol. 327, pp. 455-462, 1994. -
H.L.	AV	Schulze, European Journal of Pharmaceutical Sciences, Combined histamine H1/H2 receptor antagonists, Vol 6, pp. 177-186, 1998.
H.L.	AW	van der Goot, Eur J. Med. Chem. , Isothiourea analogues of histamine as potent agonists, Vol 27, pp. 511-517, 1992.
H.L.	AX	Walczynski, Il Farmaco, Non-imidazole histamine H3 ligands, Vo. 54, pp. 684-694, 1999.
H.L.	AY	Brown, Br. J. Pharmac. , Pharmacological studies with SK & F 93944, Vol. 87, pp. 569-578, 1986.
H.L.	AZ	West, Molecular Pharmacology, Identificatin of Two H3-Histamine Receptor Subtypes, Vol. 38, pp. 610-613, 1990.
H.L.	BA	Clapham, Brit. J. Pharm. Suppl. , Ability of the Selective Histamine H3 Receptor Antagonist, Vol. 110, pp. Abs. 65P, 00/00, 1993.
H.L.	BB	Yokoyama, European Journal of Pharmacology, Effect of Thioperamide, Vol. 234, pp 129-133, 1993.
H.L.	BC	Schlicker, Br. J. Pharmacol., Novel Histamine H3 Receptor Antagonists, Vol. 112, pp. 1043-1048, 1994.
H.L.	BD	Leurs, Progre. Drug. Res. , The Histamine H3-Receptor, Vol. 39, pp. 127-165, 00/00, 1992.

H.L.	BE	Lipp, Histamine Receptor, Pharmacochemistry of H3-Receptors, pp. 57-72, 00/00, 1992.
H.L.	BF	Stark, European Journal of Pharmaceutical Sciences, New potent Histamine H3-Receptor Vol 3, pp. 95-104, 1995.
	BG	

EXAMINER	DATE CONSIDERED
Hung Xin	3/10/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC
FEB 1
REMARKS
RECEIVED
FEB 20 2003
TECH CENTER 1600/2900